Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Colorcon
Cipla
Harvard Business School
Chinese Patent Office
Citi
Express Scripts
Dow
Daiichi Sankyo
Healthtrust

Generated: January 19, 2018

DrugPatentWatch Database Preview

Gd Searle Llc Company Profile

« Back to Dashboard

Summary for Gd Searle Llc
International Patents:94
US Patents:8
Tradenames:37
Ingredients:25
NDAs:42

Drugs and US Patents for Gd Searle Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc ENOVID mestranol; norethynodrel TABLET;ORAL-20 010976-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Gd Searle Llc POTASSIUM CHLORIDE potassium chloride INJECTABLE;INJECTION 086219-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc ALDACTAZIDE hydrochlorothiazide; spironolactone TABLET;ORAL 012616-004 Dec 30, 1982 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc CU-7 copper INTRAUTERINE DEVICE;INTRAUTERINE 017408-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc CALAN verapamil hydrochloride TABLET;ORAL 018817-003 Feb 23, 1988 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc LIDOCAINE HYDROCHLORIDE lidocaine hydrochloride INJECTABLE;INJECTION 083135-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc CLORAZEPATE DIPOTASSIUM clorazepate dipotassium CAPSULE;ORAL 071728-001 Dec 18, 1987 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Gd Searle Llc CYTOTEC misoprostol TABLET;ORAL 019268-001 Dec 27, 1988 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Gd Searle Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-002 Feb 26, 1996 ➤ Subscribe ➤ Subscribe
Gd Searle Llc CU-7 copper INTRAUTERINE DEVICE;INTRAUTERINE 017408-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Gd Searle Llc SYNAREL nafarelin acetate SPRAY, METERED;NASAL 019886-001 Feb 13, 1990 ➤ Subscribe ➤ Subscribe
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-001 Feb 26, 1996 ➤ Subscribe ➤ Subscribe
Gd Searle Llc CU-7 copper INTRAUTERINE DEVICE;INTRAUTERINE 017408-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-001 Feb 26, 1996 ➤ Subscribe ➤ Subscribe
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-001 Feb 26, 1996 ➤ Subscribe ➤ Subscribe
Gd Searle Llc FLAGYL ER metronidazole TABLET, EXTENDED RELEASE;ORAL 020868-001 Nov 26, 1997 ➤ Subscribe ➤ Subscribe
Gd Searle Llc TATUM-T copper INTRAUTERINE DEVICE;INTRAUTERINE 018205-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Gd Searle Llc COVERA-HS verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020552-002 Feb 26, 1996 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for GD SEARLE LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 50 mg/0.2 mg ➤ Subscribe 6/29/2009
➤ Subscribe Delayed-release Tablets 75 mg/0.2 mg ➤ Subscribe 11/28/2008
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 9/27/2006

Non-Orange Book US Patents for Gd Searle Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,534,089 Uniform drug delivery therapy ➤ Subscribe
6,592,902 Controlled release eplerenone compositions ➤ Subscribe
6,863,902 Immediate release eplerenone compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Gd Searle Llc Drugs

Supplementary Protection Certificates for Gd Searle Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB99/008 United Kingdom ➤ Subscribe PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
2006 00038 Denmark ➤ Subscribe PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
C/GB08/020 United Kingdom ➤ Subscribe SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.
C/GB97/005 United Kingdom ➤ Subscribe PRODUCT NAME: DOLASETRON, OR A PHARMACEUTICALLY-ACCEPTABLE ACID ADDITION OR QUATERNARY AMMONIUM SALT THEREOF; REGISTERED: UK 04425/0150 19960926
C0049 Belgium ➤ Subscribe PRODUCT NAME: NAFARELIN. ACETAT; NAT. REG.: 194 IS 46 F 11 19920616; FIRST REG.: DK D.SP.NR. 8291 19900628
C/GB98/031 United Kingdom ➤ Subscribe PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
0814 Netherlands ➤ Subscribe PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211
156 Luxembourg ➤ Subscribe PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
/2015 Austria ➤ Subscribe PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
C0021 Belgium ➤ Subscribe PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Dow
Baxter
Boehringer Ingelheim
Citi
Farmers Insurance
Fish and Richardson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot